The renal tubular secretion of cationic drugs is dominated by basolateral organic cation transporter 2 (rOCT2/SLC22A2) and luminal multidrug and toxin extrusion 1 (rMATE1/SLC47A1). Little is known about the variation in the expression of these renal transporters after liver ischemia-reperfusion (I/R) injury. Here, we examined the pharmacokinetics of a cationic drug, cimetidine, and renal rOCT2 and rMATE1 levels as well as their regulation after liver I/R. Rats were subjected to 60 min of liver ischemia followed by 12 h of reperfusion. The antioxidant Trolox μ was administered intravenously 5 min before reperfusion. The systemic and tubular secretory clearances of cimetidine (78% and 55%) as well as renal rOCT2 and rMATE1 levels (67% and 61%) in I/R rats were decreased compared with those in sham-operated rats, respectively. However, the renal tissue-to-plasma concentration ratio but not the renal tissue-to-urine clearance ratio of cimetidine was decreased after liver I/R. Moreover, Trolox prevented the decreases in renal rOCT2 levels and systemic clearance of cimetidine after liver I/R. These results demonstrate that liver I/R decreases the tubular secretion of cimetidine, mainly because of the decreased rOCT2 level in the kidney, and that oxidative stress should be responsible in part for decreased renal rOCT2 after liver I/R injury.
Introduction
The kidney mediates urinary excretion of a wide variety of xenobiotics, including drugs, toxins, and endogenous compounds. In renal proximal tubules, membrane transport proteins expressed specifically at the apical or basolateral membranes are responsible for the urinary secretion of diverse drugs. The structures and functions of organic anion transporters (OATs) and organic cation transporters (OCTs) encoded by SLC22A genes have been characterized. [1] [2] [3] rOAT1 (SLC22A6) and rOAT3 (SLC22A8) mediate organic anion/¡-ketoglutarate exchange at the basolateral membrane of the proximal tubules. 3, 4) Meanwhile, rOCT1 (SLC22A1) and rOCT2 (SLC22A2) are driven by inside-negative membrane potential, mediating basolateral uptake of diverse organic cations, 5, 6) such as cimetidine, metformin, and cisplatin. [7] [8] [9] In the kidney, rOCT2 has the highest expression levels among the OCT family. 6) Moreover, at the brush-border membranes, rat multidrug and toxin extrusion 1 (rMATE1/SLC47A1) mediates the extrusion of organic cations from the cells into the tubular lumen using the transmembrane H + gradient as a driving force 10) and is considered to be responsible for the final step of urinary excretion of cationic drugs. Therefore, the variations of the expression and/or function of these transporters in pathological conditions could impact greatly on the renal clearance of drugs.
Liver ischemia-reperfusion (I/R) injury occurs when the blood flow to the liver is transiently interrupted and subsequently reperfused in liver transplantation. 11) Liver I/R injury leads not only to injury of ischemic liver but also to that of the kidney. 12) Clinical studies have indicated that renal dysfunction following liver transplantation is common. 13) Moreover, in patients with liver disease, it is reported that both systemic and renal clearances of cimetidine are decreased compared with those in healthy volunteers, with no significant changes in the extrarenal clearance after intravenous administration of cimetidine. 14) Cimetidine is mainly eliminated from the kidney 15, 16) and its tubular secretion rate is 2.8-fold higher than the glomerular filtration rate (GFR) in rats. 17) In addition, cimetidine was reported to be transported by rOCT2, rMATE1, and rOAT3 in the kidney. 18, 19) In rats with renal disease by 5/6 nephrectomy 20) and hyperuricemia, 21) the renal clearance of cimetidine was decreased by the down-regulation of renal rOCT2 and rOAT3. Taking these findings into consideration, we hypothesized that decreased renal excretion of cimetidine in patients with liver diseases could be caused by the decreased expression and function of organic cation and anion transporters in the kidney. In liver disease, it is reported that the rOCT2 expression in the kidney is decreased in rats with ethynylestradiolinduced cholestasis. 22) After liver I/R injury, the down-regulation of multidrug resistance-associated protein 2 in the liver and its upregulation in the kidney were observed. 23) However, no information is available regarding the effect of liver I/R injury on the expression and function of renal organic cation and anion transporters.
In the present study, we examined the pharmacokinetics of cimetidine and the expression of rOCT2, rMATE1, and rOAT3 in the kidney as well as the regulatory mechanisms of these transporters after liver I/R injury.
Materials and Methods
Materials: Cimetidine and Trolox μ (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) were obtained from Nacalai Tesque (Kyoto, Japan) and Calbiochem (San Diego, CA), respectively. All other chemicals used were of the highest purity available.
Preparation of liver I/R injury model: Nine-week-old male Wistar rats (Clea, Shizuoka, Japan) were used for all experiments. The rats were fasted for 12 h before the experiments, but allowed free access to water. The experiments were approved by Mie University Review Board for Animal Investigation and were conducted according to the guidelines for animal experiments of the National Institute of Health. Liver I/R model rats were prepared according to our previous report. 24) In the case of the administration of Trolox, the experimental animals were randomly divided into four groups: sham-operated (Sham) rats treated with vehicle (Sham+Vehicle), sham-operated rats treated with Trolox (Sham+Trolox), I/R rats treated with vehicle (I/R+Vehicle), and I/R rats treated with Trolox (I/R+Trolox). Trolox dissolved in phosphate buffered saline (pH 7.4, vehicle) was injected rapidly into the cannula implanted in the right jugular vein at a dose of 2.5 mg/kg, 5 min before reperfusion, according to the methods of our previous report. 25) In vivo systemic clearance experiments: Rats were anesthetized by intraperitoneal administration of pentobarbital (50 mg/kg) at 12 h after reperfusion. Blank plasma (0.3 ml) was obtained to measure alanine aminotransferase (ALT) and creatinine in plasma. Plasma ALT and creatinine were determined using a kit obtained from Wako Pure Chemical (Osaka, Japan). Cimetidine was intravenously administered to rats at a dose of 8 mg/kg via the right femoral vein. Blood samples were collected from the right femoral artery at 1, 3, 5, 10, 15, 30, 60, 90, and 120 min after intravenous administration. Pharmacokinetic parameters such as the area under the plasma concentration-time curve (AUC) and systemic clearance (CL tot ) were calculated from plasma concentrations of cimetidine. Moreover, the plasma concentration-time curves of cimetidine were fitted to a triexponential curve according to our previous report.
26 ) The elimination rate constant from the central compartment (K el ) and distribution volume of the central compartment (V d ) were calculated according to the procedures for 3-compartmental analysis. 26) In vivo renal clearance experiments: In vivo renal clearance experiments were performed as described previously. 26) Briefly, rats were anesthetized by intraperitoneal administration of pentobarbital (50 mg/kg) at 12 h after reperfusion. Blank urine was collected from the urinary bladder for 10 min and blank blood was sampled from the femoral artery. Bolus doses of cimetidine (8 mg/kg), mannitol (146 mg/kg), and inulin (73.4 mg/kg) were administered to the femoral vein, followed by constant infusion of cimetidine (0.5 mg/ml), mannitol (40 mg/ml), and inulin (20 mg/ ml) at a rate of 2.2 ml/h using an infusion pump. Inulin clearance was used as GFR. After 60 min equilibration of constant infusion, urine samples were collected three times at 10 min intervals and blood samples were obtained at the mid-point of the urine collection. The plasma unbound fractions of cimetidine were determined by ultrafiltration using YM-10 columns (Microcon, Millipore, Billerica, MA). Renal secretory clearance was calculated using the equation CL TS = CL R ¹ f u © GFR, where CL TS is tubular secretory clearance, CL R is renal clearance, and f u is the unbound fraction. Renal luminal efflux clearance was calculated using the following equation: Luminal efflux clearance (ml/min/kg) = Urinary excreted amount (mg/kg)/Renal tissue AUC (mg0min/ml).
Determination of cimetidine in plasma, urine, and kidney: The concentrations of cimetidine in the plasma, urine, and kidney were determined by high-performance liquid chromatography (HPLC) according to the methods reported previously. 26 ) HPLC analyses were performed using an LC-20AD HPLC system (Shimadzu, Kyoto, Japan) connected to a reversed-phase Chemcobond 5-ODS-H column (4.0 © 150 mm, Chemco Scientific, Osaka, Japan) and a UV spectrophotometric detector (SPD-20A, Shimadzu). The column temperature was set at 40°C. The elution of cimetidine was conducted with 90% phosphate buffer (50 mM, pH 5.5) and 10% acetonitrile (v/v) at 1 ml/min. The detection wavelength was 235 nm.
Western blot analyses of rOCT2, rMATE1, and rOAT3: The crude membrane fractions prepared from the kidney after in vivo systemic clearance experiments were isolated according to the method in our previous report.
26 ) The protein isolated from the kidney was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Western blotting using the polyclonal antibodies for rOCT2, rOAT3, and rMATE1 (a generous gift from Prof. Ken-ichi Inui, Department of Pharmacy, Kyoto University Hospital) as well as polyclonal antibody for villin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was performed as described previously. 26) The relative densities of the bands in each lane were determined using Image J 1.38 (National Institutes of Health, Bethesda, MD), and the densitometric ratios of rOCT2, rOAT3, and rMATE1 to the corresponding villin were calculated.
27)
Statistical analyses: All data are expressed as the mean « S.D. Statistical comparisons between two groups were performed using the unpaired t-test and the differences among multiple groups were determined by one-way analysis of variance followed by Tukey's multiple comparison test with Graph Pad Prism 5.01 (Graph Pad Software Inc., San Diego, CA). The level of significance was p < 0.05.
Results

Effect of liver I/R injury on pharmacokinetics of cimetidine:
The mean plasma concentration-time profiles of intravenously administered cimetidine at 12 h after reperfusion are shown in Figure 1 . The pharmacokinetic parameters are summarized in Table 1 . The plasma concentrations of cimetidine in I/R rats were significantly higher than those in Sham rats at 3, 5, 10, 15, and 30 min after the intravenous administration of cimetidine. The AUC of cimetidine in I/R rats was increased to 128% compared with that in Sham rats, whereas the CL tot and K el in I/R rats were decreased to 78% and 67% of those in Sham rats, respectively. On the other hand, there was no significant difference in V d between Sham and I/R rats.
Renal and tubular secretory clearances of cimetidine after liver I/R injury: We investigated the urinary excretion of cimetidine in Sham and I/R rats by an in vivo renal clearance method. Although the f u and GFR of cimetidine in I/R rats were comparable to those in Sham rats, the CL R and CL TS of cimetidine in I/R rats were significantly lower by 38% and 45%, respectively, than those in Sham rats ( Table 2) . In Figure 2A , the renal tissueto-plasma concentration ratio of cimetidine in I/R rats was significantly lower than that in Sham rats, whereas there were no significant differences in luminal efflux clearances between the two groups (Fig. 2B) .
Expression levels of rOCT2, rMATE1, rOAT3, and villin in kidney after liver I/R injury: To obtain information about the mechanisms responsible for the decreased renal elimination of cimetidine after liver I/R injury, the expression levels of organic ion transporters were analyzed by Western blot analyses (Figs. 3A, 3B , and 3C). Figures 3D, 3E , and 3F show the rOCT2, rMATE1, and rOAT3 expression levels in the kidney normalized by the corresponding villin signals, respectively. While the expression levels of villin were not significantly different between Sham and I/R rats, the expression levels of rOCT2, rMATE1, and rOAT3 in I/R rats were significantly lower by 33%, 39%, and 35%, respectively, than the corresponding values in Sham rats (Figs. 3D, 3E , and 3F).
Effect of Trolox on biochemical parameters after liver I/R injury: We investigated the role of oxidative stress on hepatic and renal functions after liver I/R injury by the administration of Trolox. The levels of ALT and creatinine in plasma are summarized in Table 3 . Trolox alone showed no significant effect on the level of ALT or creatinine in plasma of Sham rats. The level of ALT but not creatinine in plasma was significantly elevated in I/R+Vehicle rats compared with that in Sham rats, indicating that liver dysfunction was induced by the liver I/R injury. However, this increased plasma ALT after liver I/R was not changed by the administration of Trolox to I/R rats. Moreover, there were no significant differences in the level of ALT or creatinine in plasma between I/R+Vehicle and I/R+Trolox rats. Results are the mean « S.D. of four rats. Bolus doses of cimetidine (8 mg/kg), mannitol (146 mg/kg), and inulin (73.4 mg/kg) were administered to the femoral vein, followed by constant infusion of cimetidine (0.5 mg/ml), mannitol (40 mg/ml), and inulin (20 mg/ml) at a rate of 2.2 ml/h. a p < 0.05 compared with Sham rats. GFR, glomerular filtration rate; f u , unbound fraction; CL R , renal clearance; CL TS , tubular secretory clearance, CL TS = CL R ¹ f u © GFR. Effect of Trolox on pharmacokinetics of cimetidine after liver I/R injury: We investigated the role of oxidative stress in the pharmacokinetics of intravenously administered cimetidine after liver I/R injury by the administration of Trolox. The pharmacokinetic parameters after intravenous administration of cimetidine (8 mg/kg) to each rat are summarized in Table 4 . Trolox alone showed no significant effect on the pharmacokinetic parameters in Sham rats. Similarly to the results shown in Table 1 , the AUC of cimetidine in I/R+Vehicle rats was increased to 127% of that in Sham rats, whereas the CL tot and K el in I/R rats were decreased to 78% and 67% of those in Sham rats, respectively. The administration of Trolox to I/R rats prevented the increase in AUC as well as decreases in CL tot and K el of cimetidine in I/R rats. On the other hand, there were no significant differences in V d among the four groups.
Effect of Trolox on the expression levels of rOCT2, rMATE1, and rOAT3 in kidney after liver I/R injury: We investigated the role of oxidative stress on decreased expression levels of renal rOCT2, rMATE1, and rOAT3 after liver I/R injury by the administration of Trolox. The expression levels of rOCT2, rMATE1, and rOAT3 were compared by Western blot analysis. Table 5 shows the results of densitometric analyses of rOCT2, rMATE1, and rOAT3 expression levels in the kidney normalized by the corresponding villin signals. Trolox alone showed no significant effect on the expression levels of rOCT2, rMATE1, or rOAT3 in Sham rats. Moreover, the expression levels of villin were not significantly different among the four groups (data not shown). The expression levels of rOCT2, rMATE1, and rOAT3 in the kidney were significantly lower in I/R+Vehicle rats than in Sham+Vehicle rats, similarly to the findings shown in Figure 3 . The administration of Trolox prevented the decrease in the expression levels of these transporters in I/R rats.
Discussion
Altered expression of transporters has been reported using several animal models with liver injury. 28) However, little information is available on the alterations in the expression of organic ion transporter in the kidney after liver I/R injury. In the present study, we evaluated the pharmacokinetics of cimetidine and the expressions of renal rOCT2, rMATE1, and rOAT3. Moreover, the regulatory mechanisms of these transporters after liver I/R injury were investigated.
The present study demonstrated that the AUC of intravenously administered cimetidine in I/R rats was increased compared with 
Results are the mean « S.D. of four or six rats. Renal tissues were collected after in vivo systemic clearance experiments. The expression levels of rOCT2, rMATE1, rOAT3, and villin in renal crude membrane were determined by Western blot analyses. Densitometric quantification of rOCT2, rMATE1, and rOAT3 was performed by normalization of the result relative to the villin signals. Sham+Vehicle levels were set at 100%. a p < 0.05 compared with Sham+Vehicle rats, b p < 0.05 compared with Sham+Trolox rats. that in Sham rats ( Table 1) . The pharmacokinetic analyses indicated decreased CL tot and K el of cimetidine in I/R rats compared with those in Sham rats, with no significant change in the V d (Table 1) . Moreover, the apparent alteration of body weight as well as distribution volume of the peripheral compartment was not observed in I/R rats (data not shown). These findings strongly suggest that the increased AUC of cimetidine after liver I/R injury is attributable to the decreased apparent clearance of cimetidine.
Approximately 70% of cimetidine administered orally is excreted from the kidney in rats, 16) indicating that cimetidine is mainly eliminated from the kidney. In the present study, the renal tubular secretion and GFR of cimetidine were evaluated in detail using an in vivo renal clearance method in Sham and I/R rats. As shown in Table 2 , the GFR and unbound fraction of cimetidine were not significantly different between Sham and I/R rats, suggesting that there was no significant change in the rate of cimetidine excretion through glomerular filtration after liver I/R injury. On the other hand, the CL R and CL TS were markedly decreased after liver I/R injury ( Table 2) . Because the present in vivo renal clearance study was carried out under diuretic conditions using the constant intravenous infusion of mannitol, 17) the contribution of tubular reabsorption of cimetidine should be minimal. Consequently, it is strongly suggested that the decreased systemic clearance of cimetidine after liver I/R injury is attributable substantially to the decreased tubular secretion in the kidney. On the other hand, it is also reported that cimetidine undergoes hepatic metabolism in part by sulfotransferase. 16) Although little information is available on the alteration in the activity of conjugation through sulfotransferase in the liver after liver I/R injury, the extrarenal clearance determined by subtracting CL R from CL tot is 19.0 and 18.8 ml/min in Sham and I/R rats, respectively, indicating that hepatic metabolism should not significantly contribute to the decreased systemic clearance of cimetidine in I/R rats.
Renal organic cation transporters, rOCT2 and rMATE1, play key roles in the tubular secretion of cimetidine at the basolateral and brush-border membranes, respectively. 10) Moreover, it is demonstrated that cimetidine is also recognized by rOAT3. 29) Therefore, we investigated the expression of rOCT2, rMATE1, and rOAT3 in the kidney after liver I/R injury. As shown in Figure 3 , the expression levels of these organic ion transporters were decreased after liver I/R injury. To our knowledge, this is the first report on the alteration in the expression of rOCT2, rMATE1, and rOAT3 in the kidney after liver I/R injury.
Although the affinity of cimetidine for rMATE1 is much stronger than that for rOCT2, 19) Terada et al. 30) reported that rOCT2 mRNA levels in the proximal tubule were approximately 10-fold higher than rMATE1 mRNA levels. Moreover, it is reported that cimetidine showed higher affinity for rOCT2 than for rOAT3, 18) and the expression levels of rOCT2 mRNA in the kidney are higher than those of rOAT3. 31) In the present study, the efflux clearance of cimetidine across apical membranes of renal tubular cells was not decreased in I/R rats with down-regulation of renal rMATE1 (Figs. 2B and 3C) , suggesting that the down-regulation of rMATE1 in the kidney has a small influence on the decreased tubular secretion of cimetidine after liver I/R injury. Meanwhile, the concentration of cimetidine in the renal tissue was decreased after liver I/R injury ( Fig. 2A) . Moreover, the decreasing rate of systemic clearance of cimetidine was comparable to that of rOCT2 expression after liver I/R injury ( Table 1 and Fig. 3 ). These findings suggest that the decreased tubular secretion of cimetidine was mainly attributable to the decreased expression levels of rOCT2 rather than rMATE1 and rOAT3 after liver I/R injury.
Various factors have been reported to be involved in liver I/R injury, such as oxidative stress, inflammatory cytokines, and activated leukocytes.
11) Interestingly, the function and expression of drug transporters in the kidney were shown to be altered in various liver injuries associated with oxidative stress.
28) The antioxidant Trolox is a potent free radical scavenger 32) and some studies have reported that Trolox protected against cardiac and renal I/R injury by preventing oxidative stress-induced lipid peroxidation. 33, 34) In our previous study, we demonstrated that Trolox prevented increases in the function and/or expression of cytochrome P450 3A and P-glycoprotein in the small intestine induced after liver I/R injury by preventing oxidative stress in plasma. 25) However, questions remain as to whether oxidative stress regulates renal tubular transporters after liver I/R injury. Therefore, we investigated the contribution of oxidative stress to the decreased expression of rOCT2, rMATE1, and rOAT3 as well as decreased systemic clearance of cimetidine after liver I/R injury by the administration of Trolox, because Trolox prevents the oxidative stress in plasma but not hepatic function, as shown in Table 3 and similarly as reported previously. 25) As shown in Tables 4 and 5, the decreases in systemic clearance of cimetidine and expression levels of rOCT2, rOAT3, and rMATE1 in the kidney after liver I/R were prevented by the administration of Trolox, suggesting that oxidative stress induced by liver I/R injury is involved at least in part in the decreased expression levels of these transporters in the kidney. Moreover, it is strongly suggested that the decreased renal tubular secretion of cimetidine is mostly attributable to the decreased expression levels of these transporters after liver I/R injury. Schneider et al. 35) reported that nitric oxide (NO) generated by inducible NO synthase (iNOS), a kind of oxidative stress, decreased the mRNA and protein levels of rOCT2 in the kidney with renal I/R injury. Moreover, Trolox attenuates iNOS mRNA expression after liver I/R injury. 36) Therefore, these findings suggest that NO produced by liver I/R injury should transcriptionally down-regulate renal rOCT2 expression. In rOAT3, our previous review indicates that the activation of protein kinase C (PKC) by oxidative stress regulates the expression and/or function of rOAT3. 28) Recently, Phatchawan et al. 37) demonstrated that the decreased function and expression of renal rOAT3 in diabetic rats are associated with the activation of the PKC signaling pathway through oxidative stress, suggesting that decreased renal rOAT3 expression is attributable to the activation of PKC through oxidative stress after liver I/R injury. On the other hand, little information is available on the role of oxidative stress in the expressional regulation of rMATE1. Further studies are needed to clarify other factors that mediate alteration of the expression levels of renal drug transporters after liver I/R injury.
In conclusion, our study demonstrates for the first time that liver I/R injury decreases the tubular secretion of cimetidine, mainly because of the decreased expression of rOCT2 in the kidney, and that oxidative stress should be responsible in part for decreased renal rOCT2 after liver I/R injury. The present findings also provide useful information for our understanding of the renal disposition of cationic drugs in liver I/R injury.
